Verastem (VSTM) Cash & Equivalents (2011 - 2026)

Verastem's Cash & Equivalents history runs 16 years deep, the most recent figure standing at $181.7 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 54.55% year-over-year to $181.7 million in Q1 2026; TTM through Mar 2026 was $181.7 million, a 54.55% increase from a year earlier, with the FY2025 full-year figure at $205.0 million, up 130.8% from the prior year.
• Cash & Equivalents eased to $181.7 million in Q1 2026 per VSTM's latest filing, from $205.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $205.0 million in Q4 2025 and bottomed at $46.7 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $95.0 million (2023), against an average of $111.4 million.
• Across the five-year window, Cash & Equivalents soared 221.49% in 2022 and slumped 54.46% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $79.1 million in 2022, then decreased by 1.48% to $77.9 million in 2023, then climbed by 14.0% to $88.8 million in 2024, then soared by 130.8% to $205.0 million in 2025, then dropped by 11.36% to $181.7 million in 2026.
• Per Business Quant, the three latest VSTM Cash & Equivalents figures stand at $181.7 million (Q1 2026), $205.0 million (Q4 2025), and $137.7 million (Q3 2025).